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Cytomegalovirus (CMV) is a pathogen of emerging
importance for patients with septic shock. In this prospec-
tive study, 25 immunocompetent CMV-seropositive patients
with septic shock and an intensive care unit stay of >7 days
were monitored by using quantitative pp65-antigenemia
assay, shell vial culture, and virus isolation. Within 2 weeks,
active CMV infection with low-level pp65-antigenemia
(median 3 positive/5×105 leukocytes) developed in 8 (32%)
patients. Infection was controlled within a few weeks (medi-
an 26 days) without use of antiviral therapy. Duration of
intensive care and mechanical ventilation were significant-
ly prolonged in patients with active CMV infection. CMV
reactivation was associated with concomitant herpes sim-
plex virus reactivation (p = 0.004). The association
between active CMV infection and increased illness could
open new therapeutic options for patients with septic
shock. Future interventional studies are required.
S
epsis and septic shock are defined as a clinical syn-
drome with severe inflammatory response (1). Despite
the availability of antimicrobial, antifungal, and supportive
therapies, septic shock is fatal for about one third of
patients.
Cytomegalovirus (CMV) is a human β-herpesvirus that
has high seroprevalence in adults. CMV disease predomi-
nantly occurs as an opportunistic infection in patients with
severe immunosuppression and rarely occurs in immuno-
competent patients (2). Clinical diagnosis of CMV disease,
without the use of virus diagnostics, is hampered by the
fact that the clinical signs and symptoms are not very spe-
cific. Patients in intensive care units (ICUs) are rarely
monitored for active CMV infection; therefore, the devel-
opment of active CMV infection remains unrecognized in
most critically ill patients.
During recent years, CMV has been discussed as an
emerging pathogen in critically ill patients who are not
receiving immunosuppressive therapy; however, the inci-
dence of active CMV infection is controversial (3,4), and
not all centers detected active CMV infections in these
patients (5–7). Among critically ill patients, the highest
incidence of active CMV infection was in patients with
septic shock (3). The causality of sepsis, consecutive CMV
reactivation, and CMV-associated pulmonary disease is
supported by a mouse model of murine CMV reactivation
after cecal ligation and puncture (8,9). Many factors could
stimulate CMV reactivation in patients with septic shock;
e.g., proinflammatory cytokines (10,11), transient immune
paralysis (compensatory antiinflammatory response syn-
drome) (12), and drugs (13).
This pilot study investigated the incidence and the nat-
ural course of active CMV infection in patients with septic
shock and different strategies for CMV monitoring. The
study may stimulate future interventional trials aimed at
preventing CMV-associated illness of patients with septic
shock.
Patients and Methods
Patients
For 9 consecutive months, patients in the anesthesio-
logic ICU, University Hospital Ulm, Ulm, Germany, who
had septic shock, were monitored for active CMV infec-
tion. We did not monitor patients who underwent splenec-
tomy, transplantation patients, or patients receiving
immunosuppressive therapy. Also, patients who had been
in ICU <7 days were excluded because CMV reactivation
and CMV-associated illness were expected to develop with
a time delay. To define septic shock, we used the criteria
established by the American College of Chest
Physicians/Society of Critical Care Medicine (14).
Clinicians were not made aware of virologic results. To
avoid exogenous CMV infections, transfusions were limit-
ed to filtered leukocyte-reduced blood products. The study
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Virologic Examinations
CMV monitoring was performed twice during the first
week of the study and once a week thereafter until the
patient was discharged from ICU. Quantitative pp65-anti-
genemia assay; shell vial culture; and viral isolation in
leukocytes, urine, and bronchial aspirate were performed
as previously described (15). Briefly, pp65 antigenemia
was determined in blood collected in EDTAtubes and sub-
jected to dextran sedimentation (1% dextran in phosphate-
buffered saline). Duplicates of 5×105 leukocytes were
placed onto glass slides, and the pp65 antigen-positive
cells were evaluated by immunofluorescence assay (IFA)
by using a mixture of 2 monoclonal mouse anti-pp65 anti-
bodies (20:1; Virion, Rüschlikon, Switzerland; Argene
Biosoft, Viva Diagnostika, Hürth, Germany) and goat anti-
mouse immunoglobulin (Ig) G (Dianova, Hamburg,
Germany) conjugated with fluorescein isothiocyanate
(FITC).
Leukocytes, bronchial aspirate, and urine were investi-
gated by shell vial culture and viral isolation with human
embryonic lung fibroblasts. Three days after infection,
shell vial cultures were fixed with methanol and analyzed
by IFA (anti-CMV immediate early antibody, Argene
Biosoft, Viva Diagnostika; FITC-conjugated goat anti-
mouse IgG, Dianova). Phase contrast microscopy was used
to analyze viral isolation for >6 weeks. Cytopathic effects
of various viruses were confirmed by using viral typing
with IFA and monoclonal antibodies.
At the initial evaluation, the following antibodies were
determined semiquantitatively by using ELISA (Medac,
Hamburg, Germany): CMV IgG, CMV IgM, and herpes
simplex virus (HSV) IgG. Patients with antibody indices
>1 were considered antibody positive.
Clinical Data
The following values were regularly recorded: body
temperature, heart rate, blood pressure, respiratory rate,
need for mechanical ventilation, oxygen supply (FiO2),
urinary output, hemodiafiltration, partial pressure of oxy-
gen in arterial blood, pH, leukocyte count, platelet count,
serum bilirubin, aspartate aminotransferase (AST), C-reac-
tive protein, and serum creatinine. The severity of organ
failure over time was recorded by monitoring the most rel-
evant organ functions (pulmonary, cardiovascular, hemato-
logic, hepatic) and using the Sepsis-related Organ Failure
Assessment Score (SOFA) (16). Impairment of the central
nervous system was not evaluated (Glasgow Coma Scale)
because most patients received sedatives.
Statistics
Statistical analysis was performed by using nonpara-
metric tests (Fisher exact test, Mann-Whitney U test) and
GraphPad Prism 3.02 software (GraphPad Software, San
Diego, CA, USA). Significance level was set at p = 0.05.
Results
Patients
Among 375 patients in ICU, 38 consecutive patients
with septic shock were eligible, but 13 were excluded
because of CMV seronegativity (n = 5), immunosuppres-
sive therapy (n = 2), or ICU stay <7 days (n = 6). Thus, 25
CMV-seropositive patients with septic shock and an ICU
stay >7 days were enrolled in the study.
Active CMV Infection
During the first 2 weeks after onset of septic shock,
active CMV infection was detected by sensitive quantita-
tive pp65-antigenemia assay in 8 (32%) patients (15).
Active CMV infection was also detected by shell vial cul-
ture in 4 of these patients (in bronchial aspirate for 3
patients and in urine for 1). For 1 patient for whom shell
vial culture in bronchial aspirate was positive, shell vial
culture was also positive in leukocytes. Initial detection of
active CMV infection was delayed when using shell vial
culture (detected 1, 11, 20, and 21 days after onset of sep-
tic shock) compared with pp65-antigenemia in the same
patients (0, 7, 10, and 14 days). Overall, pp65-antigenemia
was low (median 3 positive/5×105 leukocytes; range 1–17)
and became nondetectable with no antiviral therapy (medi-
an 26 days after onset of active CMVinfection; range 1–61
days). One patient died while CMV infection was still
active.
CMV IgM antibodies were found in 2 (25%) of 8
patients with and 2 (12%) of 17 patients without active
CMV infection, a difference that was not significant. Also
the quantitative levels of CMVIgG and IgM antibodies did
not differ between groups with and without active CMV
infection (Table).
Characteristics of Patients with and 
without Active CMV Infection
Patient characteristics such as age, sex, primary dis-
ease, and severity of organ failure at time of entry into the
study did not differ between patients with and without
active CMV infection (Table). Hydrocortisone (200
mg/day) was given to patients in both groups; no differ-
ences between groups were noted in body temperature,
leukocyte count, platelet count, serum creatinine level,
serum bilirubin level, AST level, and C-reactive protein
level. Systemic infection by gram-positive and gram-
negative microorganisms was detected equally in both
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dysfunction was similar for both groups. 
Overall, the severity of sepsis-related failure of multi-
ple organs, determined by SOFA score (16), did not differ
between patients with and without active CMV infection;
however, patients with active CMV infection required
mechanical ventilation and ICU therapy for a longer time
than did patients without active CMV infection (p =
0.0025) (Table). Although mortality rates were not signifi-
cantly different between patients with and without active
CMV infection (63% vs 35%; p > 0.05), the deaths
occurred later (median 44 days after onset of septic shock,
range 24–72 days) for patients with active CMV infection
than for patients without (median 21 days, range 14–35
days) (p = 0.03).
The clinical course of patients with positive CMV shell
vial culture in bronchial aspirate was associated with the
longest duration of mechanical ventilation (47, 50, and 80
days) and of ICU stay (50, 71, and 87 days); however,
because of the low number of cases, statistical analysis
was not performed.
Other Viral Infections
All 25 patients were HSV seropositive; viral isolation
in bronchial aspirate showed reactivation of HSV in 8
(32%) patients, thereby showing for the first time that
HSV and CMV reactivation were associated (p = 0.004,
Table) and occurred simultaneously (Figure). Active HSV
infections developed without skin or mucosal rash (occult
HSV infection). Because of the low number of cases, the
clinical outcome of patients with active CMV, HSV, or
CMV/HSV coinfection could not be further differentiated.
Viral isolation in bronchial aspirate and urine did not
detect additional opportunistic viral infections such as
polyoma BK virus and exogenous viral infections such as
adenovirus, respiratory syncytial virus, and parainfluenza-
virus in any patient.
Discussion
While CMV is well known as a cause of serious illness
in immunosuppressed patients, it is now being discussed
as a pathogen of emerging importance for patients with
septic shock. Generally, active CMV infection is not
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are not routinely monitored for CMV infection.
CMV reactivation developed in one third of our
patients within 2 weeks of onset of septic shock, as has
been found in studies using a similar prospective study
design (3,11). Diagnostic assays of different sensitivity,
different patient groups, and study designs could account
for discrepant results obtained by other groups (5,10).
Thus, onset of active CMV infection was detected later in
the retrospective studies (4,17,18).
Active CMV infection in patients with septic shock was
characterized by a low viral load and resolved within a few
weeks without antiviral therapy. We hypothesize that upon
CMV reactivation, patients with septic shock could mount
a protective antiviral immune response, which was differ-
ent from the immune response of most patients after trans-
plantations (19); however, this hypothesis remains to be
confirmed.
In a previous study we compared different assays for
CMV monitoring of patients with organ transplants and
demonstrated equal sensitivity of our pp65 antigenemia
assay and CMV PCR of blood cells but lower sensitivity of
shell vial culture, CMV PCR in plasma, and CMV mRNA
detection by nucleic acid sequence-based amplification
(15). Because of low viral loads, the incidence of active
CMV infection could be easily underestimated by less sen-
sitive assays for patients with septic shock, which was
shown here in that shell vial culture in blood cells detect-
ed only 1 patient with active CMVinfection. Less sensitive
assays could have been also the problem of studies that
failed to detect active CMV infection in critically ill
patients (5–7). We assume that assays with sensitivity sim-
ilar to that of our pp65-antigenemia assay (e.g., CMV PCR
of blood cells) may be equally used for CMV monitoring
of patients with septic shock, considering the results of
patients who had received transplants (3,11,15).
Shell vial culture was more likely to detect active CMV
infection in bronchial aspirate than in urine or blood cells.
Pulmonary CMV infection may be relevant for patients
with septic shock (8,20). Shell vial culture of urine was
rarely positive for CMV in patients with septic shock, a
finding which differed for patients having received a kid-
ney transplant (21). 
As expected, quantitative analysis of CMV IgG and
IgM antibodies could not discriminate between patients
with and without active CMV infection. CMV IgG anti-
bodies were analyzed to identify patients with previous
CMV infection (CMV-seropositive patients); however,
diagnosis of active CMV infection by detection of CMV
IgM antibodies or rising CMVantibody titers are no longer
recommended when sensitive CMV monitoring by pp65-
antigenemia assay or CMV PCR are available because the
information they provide is limited.
The clinical role of active CMV infection in patients
with septic shock is an area of ongoing discussion (4). We
demonstrated that active CMV infection is associated with
prolonged ventilation time and ICU stay. Ventilation time
and ICU stay were more prolonged in a subgroup of
patients for whom shell vial culture in bronchial aspirate
was positive. CMV infection was associated with pul-
monary disease despite low pp65 antigenemia and self-
limiting CMV infection. We suppose that
immunopathologic mechanisms could contribute to CMV-
associated illness (22) in addition to direct cytopathic
effects of the infection (20). Association of tumor necrosis
factor and pulmonary immunopathologic features of active
CMV infection was recently confirmed in a mouse model
showing murine CMV reactivation after cecal ligation and
puncture (9).
Deaths occurred later for patients with active CMV
infection than for those without active CMV infection.
This finding could be the consequence of CMV-associated
disease, as has been suggested (17). Although our study
was not designed to clarify the causality between active
CMV infection and increased illness, we argue that active
CMV infection increases illness and not vice versa. In the
mouse model of CMV reactivation, the causality between
sepsis, CMV reactivation, and pulmonary disease has
already been shown (9).
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Figure. First detection of cytomegalovirus (CMV) and herpes sim-
plex virus (HSV) reactivation after onset of septic shock. Incidence
of active CMV and HSV infection is shown for patients with active
CMV infection (group 1; n = 8) and without active CMV infection
(group 2; n = 17). CMV reactivation occurred during the first 2
weeks after onset of septic shock (median 7 days) and was asso-
ciated with HSV reactivation, which occurred during the same peri-
od. The incidence of active HSV infection was different between
groups 1 and 2 (75% vs 12%; p = 0.004). Active CMV infection
was detected first by CMV pp65 antigenemia; active HSV infection
was detected by virus isolation of bronchial aspirates.Recently, reactivations of HSV and human herpesvirus
6 have been reported in critically ill patients (7,23). We
demonstrated for the first time an association between
active HSV and CMV infection (p = 0.004). HSV was iso-
lated from bronchial aspirate in the absence of skin and
mucosal lesions, whereas other herpesviruses, such as
varicella-zoster virus, could not be isolated. The coinci-
dence of HSV and CMV reactivation during the first 2
weeks of septic shock suggests a common trigger mecha-
nism for herpesvirus reactivations. In future studies, more
sensitive assays (e.g., PCR) may be used to analyze the
incidence of other occult herpesvirus reactivations.
Reactivation of polyoma BK virus, which commonly caus-
es opportunistic infection after transplantation, was not
detected by virus isolation.  This finding leads to the
hypothesis that the conditions that stimulate polyomavirus
reactivation and those that stimulate CMV and HSV reac-
tivation may differ. The absence of exogenous viral infec-
tion (e.g., adenovirus, respiratory syncytial virus,
parainfluenzavirus) strengthens the suggestion that exoge-
nous nosocomial viral infections are uncommon in patients
in ICUs (24). Thus, monitoring for viral infections could
focus on endogenous herpesvirus reactivations in patients
with septic shock. Immunosuppression and  proinflamma-
tory cytokines, drugs, or combinations are presumed to be
involved in herpesvirus reactivations; however, the exact
mechanisms are still elusive for patients with septic shock
(13,25).
After organ transplants, CMV-associated illness and
death could be reduced by early antiviral therapy; however,
delayed therapy has been less effective (2). Anecdotal
reports show that critically ill patients with already estab-
lished CMV organ disease may not benefit from antiviral
therapy (3,4,20). The effect of preemptive antiviral therapy
or antiviral prophylaxis has not been tested so far in patients
with septic shock; however, in the mouse model, prophylac-
tic treatment with ganciclovir prevented murine CMV reac-
tivation and CMV-associated pulmonary fibrosis (9).
Despite the low patient number in this and previous
studies, we suggest that CMV is a pathogen of emerging
importance that can no longer be ignored for patients with
septic shock. Thus, interventional studies aimed at pre-
venting CMV-associated illness in patients with septic
shock are needed.
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